618
comprehensive health care network in the National Capital region and an Ignite
founding partner, will play a key role in the Institute’s development by contributing
state-of-the art health care facilities focused on disease prevention and personalized
medicine. Inova will be the initial clinical arm for the application of new therapeu-
tics, diagnostics and devices that target the molecular underpinnings of disease.
Ignite will house technologies that include genome sequencing systems, a transcrip-
tional profi ling facility, a proteomics and metabolomics scanning facility, and facili-
ties for molecular scanning. The institute’s research specialties will be cancers,
neurological and mental health disorders, diabetes and other metabolic diseases,
pediatric diseases, and cardiovascular diseases.
Indiana University Institute for Personalized Medicine
In 2011, Indiana University (IU) used $11.3 million to start the Indiana Institute for
Personalized Medicine, which is pursuing genome-based and pharmacogenomics
studies in cardiology, obstetrics, pediatrics, cancer, and other areas. The institute
will conduct research, train new specialists in personalized medicine, and work to
translate its discoveries into more precise therapeutics. The training program will be
funded and supported through the new Brater Scholarship in Personalized Medicine.
A panel of IU scientists will form an advisory panel that will aid other researches to
move their research beyond the laboratory stages. The new institute will also will
receive funding and support from the IU School of Medicine and its Department of
Medicine, The Indiana University-Purdue University Indianapolis, the Indiana
Physician Scientist Initiative, and the Indiana University Melvin and Bren Simon
Cancer Center.
In 2012, IU launched a new $150 million, 5-year effort that will use genetics and
personalized medicine, among other approaches, to develop new capabilities and
translational research projects focused on cancer, neuroscience, and cardiovascular
medicine. The funding will be used to support research projects, to recruit new sci-
entists in selected fi elds, and to retain current scientists at the IU School of Medicine.
The new initiative will support research that uses genetic technologies to develop
personalized therapies that could be more effective and effi cient for individuals and
healthcare providers, and also will fund translational projects and clinical trials.
One of the new initiatives will enable the IU and Bren Simon Cancer Center to
achieve NCI’s ‘comprehensive’ status, and will involve the recruitment of leading
cancer researchers and the expansion of cancer clinical trials. Under the cardiovas-
cular initiative, the partners will develop a cardiovascular genetics program and
recruit a scientist in the fi eld, and will develop a comprehensive program for the
study and treatment of heart failure across the lifespan. The neuroscience research
program will involve research into a wide range of brain injuries, neurodegenerative
disorders, and neurodevelopmental disorders.
20 Development of Personalized Medicine